<div class="_item1_gldt3_1" id="overview">
 <h2 class="_title_gldt3_1">
  <span>
   Overview
  </span>
 </h2>
 <!-- -->
 <div class="_item2_gldt3_15" id="basic">
  <h3 class="_title_gldt3_1">
   <span>
    Basic Info
   </span>
  </h3>
  <div class="_content_gldt3_7">
   <!--[-->
   <div class="ant-descriptions ant-descriptions-middle _middle_l74zf_24 _horizontal_l74zf_18 _drugDetailDirection_19rjs_1">
    <!-- -->
    <div class="ant-descriptions-view">
     <table>
      <tbody>
       <!--[-->
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--drugType">
            Drug Type
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--drugType">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               Monoclonal antibody
               <!--]-->
               <!-- -->
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--synonyms">
            Synonyms
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--synonyms">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span>
                Alzumab-L,
               </span>
               <span>
                Anti-CD6 monoclonal antibody,
               </span>
               <span>
                Anti-CD6 monoclonal antibody h-T1
               </span>
               <!--]-->
               <span class="ml-2 flex flex-shrink-0 items-center">
                <!--[-->
                <div class="inline-flex h-full">
                 <div class="inline-flex max-w-full">
                  <!--[-->
                  <div class="inline-flex cursor-pointer items-center text-yellow-600">
                   <svg class="mr-[2px]" fill="currentColor" height="1.2em" viewbox="0 0 10 16" width="1.2em">
                    <path d="M9.70678 6.27142H5.92999L6.67408 0.15021C6.68107 0.0907286 6.65118 0.0334335 6.60111 0.0103023C6.55104 -0.0128288 6.49315 0.00392205 6.45976 0.0512057L0.0610803 9.20641C-0.00721034 9.30424 -0.0192403 9.43647 0.0300607 9.54737C0.0793617 9.65827 0.181418 9.72854 0.293217 9.72858H4.07001L3.32592 15.8498C3.31893 15.9093 3.34882 15.9666 3.39889 15.9897C3.44896 16.0128 3.50685 15.9961 3.54024 15.9488L9.93892 6.79359C10.0072 6.69576 10.0192 6.56353 9.96994 6.45263C9.92064 6.34174 9.81858 6.27146 9.70678 6.27142Z" fill-rule="evenodd">
                    </path>
                   </svg>
                   <span class="">
                    + [13]
                   </span>
                  </div>
                  <!--]-->
                 </div>
                </div>
                <!--]-->
               </span>
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--target">
            Target
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--target">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--target" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/target/8b9f83d4766e41bd8a3eb97584fc646f" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 <span class="">
                  CD6
                 </span>
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <!--]-->
               <!-- -->
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--action">
            Action
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--action">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span>
                inhibitors
               </span>
               <!--]-->
               <!-- -->
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--mechanism">
            Mechanism
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--mechanism">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span class="">
                CD6 inhibitors(T-cell differentiation antigen CD6 inhibitors),
               </span>
               <span class="">
                T lymphocytes inhibitors
               </span>
               <!--]-->
               <!-- -->
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--therapeutic">
            Therapeutic Areas
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--therapeutic">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/76732dd51f2842799e6843eef80820ea" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Immune System Diseases
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/63ed6e7cb91a42928300df21dd9d3ac1" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Skin and Musculoskeletal Diseases
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/67034410be134e2bbb5b0930595b5e75" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Other Diseases
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <!--]-->
               <span class="ml-2 flex flex-shrink-0 items-center">
                <!--[-->
                <span class="">
                 + [5]
                </span>
                <!--]-->
               </span>
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--activeDisease">
            Active Indication
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--activeDisease">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/4877fdea8af24861ac4d9dd0d5baab7f" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Cytokine Release Syndrome
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/d281a3b362a740d8aeb63e2a10102671" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Plaque psoriasis
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/116fbe2167a648e6b4ca70ccdfb4af57" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Acute Graft Versus Host Disease
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <!--]-->
               <span class="ml-2 flex flex-shrink-0 items-center">
                <!--[-->
                <span class="">
                 + [7]
                </span>
                <!--]-->
               </span>
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--inActiveDisease">
            Inactive Indication
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--inActiveDisease">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/15fe4881cb88431eb9d44b018619d7b0" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Asthma
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/717a9bf79e584830859595b8dbe9d433" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 COVID-19
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/310dc3b138284382bfbb6ffc7eceaf41" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Lupus Erythematosus, Cutaneous
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <!--]-->
               <span class="ml-2 flex flex-shrink-0 items-center">
                <!--[-->
                <span class="">
                 + [2]
                </span>
                <!--]-->
               </span>
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <!--]-->
      </tbody>
     </table>
    </div>
   </div>
   <div class="ant-descriptions ant-descriptions-middle _middle_l74zf_24 _horizontal_l74zf_18 _drugDetailDirection_19rjs_1">
    <!-- -->
    <div class="ant-descriptions-view">
     <table>
      <tbody>
       <!--[-->
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--originOrg">
            Originator Organization
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--originOrg">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--organization" style="background:;color:;">
                <!--[-->
                <span class="mr-1 h-5 w-5 flex-shrink-0">
                 <!--[-->
                 <span class="_avatar_3wddt_11 ant-avatar ant-avatar-square ant-avatar-image" data-testid="ui-avatar" style="width:20px;height:20px;line-height:20px;font-size:18px;">
                  <img alt="Biocon Ltd." src="https://images.crunchbase.com/image/upload/t_cb-default-original/v1397206829/68af2f8bafa6fe71a6dccdba3db3582f.gif"/>
                 </span>
                 <!--]-->
                </span>
                <a class="flex-1 truncate text-black" href="/organization/2b815ae18447e49250ecc95fcb7f80bc" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Biocon Ltd.
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <!--]-->
               <!-- -->
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--activeOrg">
            Active Organization
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--activeOrg">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--organization" style="background:;color:;">
                <!--[-->
                <span class="mr-1 h-5 w-5 flex-shrink-0">
                 <!--[-->
                 <span class="_avatar_3wddt_11 ant-avatar ant-avatar-square ant-avatar-image" data-testid="ui-avatar" style="width:20px;height:20px;line-height:20px;font-size:18px;">
                  <img alt="Biocon Ltd." src="https://images.crunchbase.com/image/upload/t_cb-default-original/v1397206829/68af2f8bafa6fe71a6dccdba3db3582f.gif"/>
                 </span>
                 <!--]-->
                </span>
                <a class="flex-1 truncate text-black" href="/organization/2b815ae18447e49250ecc95fcb7f80bc" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Biocon Ltd.
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--organization" style="background:;color:;">
                <!--[-->
                <span class="mr-1 h-5 w-5 flex-shrink-0">
                 <!--[-->
                 <span class="_avatar_3wddt_11 ant-avatar ant-avatar-square ant-avatar-image" data-testid="ui-avatar" style="width:20px;height:20px;line-height:20px;font-size:18px;">
                  <img alt="Equillium, Inc." src="https://images.crunchbase.com/image/upload/t_cb-default-original/arih9xyddcmijduthvj7"/>
                 </span>
                 <!--]-->
                </span>
                <a class="flex-1 truncate text-black" href="/organization/9a87f1276df9f3c91b1f567122397d88" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Equillium, Inc.
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--organization" style="background:;color:;">
                <!--[-->
                <span class="mr-1 h-5 w-5 flex-shrink-0">
                 <!--[-->
                 <span class="_avatar_3wddt_11 ant-avatar ant-avatar-square ant-avatar-image" data-testid="ui-avatar" style="width:20px;height:20px;line-height:20px;font-size:18px;">
                  <img alt="Biotech Pharmaceutical Co., Ltd." src="https://filecdn.shuidi.cn/img/upload/images_logo/52/1e/87/521e87a84dd787a4e7efbd01b59d0b3e.png/0x0.png"/>
                 </span>
                 <!--]-->
                </span>
                <a class="flex-1 truncate text-black" href="/organization/6e991247a81c0bd7242a0c14895f4963" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Biotech Pharmaceutical Co., Ltd.
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <!--]-->
               <!-- -->
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--inActiveOrg">
            Inactive Organization
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--inActiveOrg">
            <!--[-->
            <span>
             <!--[-->
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--organization" style="background:;color:;">
                <!--[-->
                <span class="mr-1 h-5 w-5 flex-shrink-0">
                 <!--[-->
                 <span class="_avatar_3wddt_11 ant-avatar ant-avatar-square" data-testid="ui-avatar" style="width:20px;height:20px;line-height:20px;font-size:18px;">
                  <span class="ant-avatar-string" style="opacity:0;">
                   <!-- -->
                  </span>
                 </span>
                 <!--]-->
                </span>
                <a class="flex-1 truncate text-black" href="/organization/8db90b039b61e1c617dcd0167a5b62eb" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Biotech Pharmaceuticals Pty Ltd
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <!--]-->
               <!-- -->
              </div>
              <!--]-->
             </span>
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--globalPhase">
            Drug Highest Phase
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--globalPhase">
            <!--[-->
            <span>
             <!--[-->
             <span class="_tag_5lm5p_1 _primary_5lm5p_10 _small_5lm5p_31 _plain_5lm5p_10" style="background:;color:;">
              <!--[-->
              <span class="">
               Approved
              </span>
              <!--]-->
             </span>
             <!-- -->
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--approvalDate">
            First Approval Date
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--approvalDate">
            <!--[-->
            <div class="flex flex-wrap items-center">
             <span class="mr-1">
              India (01 Jan 2013),
             </span>
             <span style="--bdf8c0bc:14px;">
              <!--[-->
              <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
               <!--[-->
               <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1 ml-1" data-testid="entity-tag--disease" style="background:;color:;">
                <!--[-->
                <!-- -->
                <a class="flex-1 truncate text-black" href="/disease/d281a3b362a740d8aeb63e2a10102671" rel="noopener" target="_blank">
                 <!--[-->
                 <!--[-->
                 Plaque psoriasis
                 <!--]-->
                 <!--]-->
                </a>
                <!-- -->
                <!-- -->
                <!--]-->
               </span>
               <!--]-->
               <!-- -->
              </div>
              <!--]-->
             </span>
            </div>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <tr class="ant-descriptions-row">
        <!--[-->
        <td class="ant-descriptions-item" colspan="1" style="">
         <div class="ant-descriptions-item-container">
          <span class="ant-descriptions-item-label" style="width:190px;">
           <!--[-->
           <span class="_label_l74zf_1" data-testid="descriptions-item__label--regulation">
            Regulation
           </span>
           <!--]-->
          </span>
          <span class="ant-descriptions-item-content" style="max-width:100%;">
           <!--[-->
           <span class="_content_l74zf_6" data-testid="descriptions-item__value--regulation">
            <!--[-->
            <span>
             <!--[-->
             <!--[-->
             <span>
              Orphan Drug (European Union),
             </span>
             <span>
              Fast Track (United States)
             </span>
             <!--]-->
             <!--]-->
            </span>
            <!--]-->
           </span>
           <!--]-->
          </span>
         </div>
        </td>
        <!--]-->
       </tr>
       <!--]-->
      </tbody>
     </table>
    </div>
   </div>
   <div class="inline-flex max-w-full mt-4 w-full">
    <div class="_tipsContainer_b7pjb_1 _yellow_b7pjb_30 _tipsBorder_b7pjb_9" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
     <!--[-->
     <!--]-->
     <svg class="h-4 w-[10px]" fill="currentColor" height="1.2em" viewbox="0 0 10 16" width="1.2em">
      <path d="M9.70678 6.27142H5.92999L6.67408 0.15021C6.68107 0.0907286 6.65118 0.0334335 6.60111 0.0103023C6.55104 -0.0128288 6.49315 0.00392205 6.45976 0.0512057L0.0610803 9.20641C-0.00721034 9.30424 -0.0192403 9.43647 0.0300607 9.54737C0.0793617 9.65827 0.181418 9.72854 0.293217 9.72858H4.07001L3.32592 15.8498C3.31893 15.9093 3.34882 15.9666 3.39889 15.9897C3.44896 16.0128 3.50685 15.9961 3.54024 15.9488L9.93892 6.79359C10.0072 6.69576 10.0192 6.56353 9.96994 6.45263C9.92064 6.34174 9.81858 6.27146 9.70678 6.27142Z" fill-rule="evenodd">
      </path>
     </svg>
     <!--[-->
     <span class="_text_b7pjb_17">
      Login to view timeline
     </span>
     <!--]-->
    </div>
   </div>
   <!--]-->
  </div>
 </div>
 <div class="_item2_gldt3_15" id="structure">
  <h3 class="_title_gldt3_1">
   <span>
    Structure/Sequence
   </span>
  </h3>
  <div class="_content_gldt3_7">
   <!--[-->
   <!-- -->
   <!-- -->
   <!-- -->
   <div class="mt-4 space-y-16" data-testid="drug-sequence-card">
    <!--[-->
    <div class="hidden lg:block" data-testid="drug-sequence-card__item">
     <div class="flex flex-wrap items-center">
      <span class="text-sm" data-testid="drug-sequence-card__item__code">
       Sequence Code 9929926
      </span>
      <!--[-->
      <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 ml-3" style="background:;color:;">
       <!--[-->
       H
       <!--]-->
      </span>
      <!--]-->
     </div>
     <img alt="sequence" class="mt-2 w-full object-contain" src="https://synapse-static.patsnap.com/ssr/98fedd7e/_nuxt/sequence.6e52690d.png"/>
     <div class="mt-2 flex items-center text-sm">
      Source:
      <!--[-->
      <span class="inline-flex h-5 items-center _mosaic_dzucl_1">
       <!--[-->
       *****
       <!--]-->
      </span>
      <!--]-->
     </div>
     <!-- -->
     <!-- -->
    </div>
    <div class="hidden lg:block" data-testid="drug-sequence-card__item">
     <div class="flex flex-wrap items-center">
      <span class="text-sm" data-testid="drug-sequence-card__item__code">
       Sequence Code 9929950
      </span>
      <!--[-->
      <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 ml-3" style="background:;color:;">
       <!--[-->
       L
       <!--]-->
      </span>
      <!--]-->
     </div>
     <img alt="sequence" class="mt-2 w-full object-contain" src="https://synapse-static.patsnap.com/ssr/98fedd7e/_nuxt/sequence.6e52690d.png"/>
     <div class="mt-2 flex items-center text-sm">
      Source:
      <!--[-->
      <span class="inline-flex h-5 items-center _mosaic_dzucl_1">
       <!--[-->
       *****
       <!--]-->
      </span>
      <!--]-->
     </div>
     <!-- -->
     <!-- -->
    </div>
    <!--]-->
   </div>
   <!--]-->
  </div>
 </div>
 <div class="_item2_gldt3_15" id="related">
  <h3 class="_title_gldt3_1">
   <span>
    Related
   </span>
  </h3>
  <div class="_content_gldt3_7">
   <!--[-->
   <div>
    <div class="mb-4 break-all text-sm text-black">
     <div class="inline-flex max-w-full">
      <!--[-->
      <span class="cursor-pointer font-semibold text-seo-blue-500 underline" data-testid="related-clinical-count">
       23
      </span>
      <!--]-->
     </div>
     <span>
      Clinical Trials associated with Itolizumab
     </span>
    </div>
    <!--[-->
    <div class="_container_8x5ka_1 _clinicalCard_1rpuv_1" data-testid="clinical-document-card">
     <!-- -->
     <!--[-->
     <div class="_container_afoc1_1 border">
      <div class="_subTitle_afoc1_14">
       <!--[-->
       <div class="flex flex-wrap items-center justify-start">
        <div class="inline-flex max-w-full">
         <div class="_tipsContainer_b7pjb_1 _normal_b7pjb_23" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
          <!--[-->
          <!--]-->
          <!-- -->
          <!--[-->
          <!--[-->
          <span class="text-green-500" data-testid="clinical-document-card__register-number">
           NCT05978544
          </span>
          <!--]-->
          <!--]-->
         </div>
        </div>
        <span class="mx-1 text-grey-450">
         /
        </span>
        <span class="_tag_5lm5p_1 _default_5lm5p_20 _mini_5lm5p_55" data-testid="clinical-study-status" style="background:#FAECDA;color:#A85604;">
         <!--[-->
         <span class="">
          Not yet recruiting
         </span>
         <!--]-->
        </span>
        <span class="_tag_5lm5p_1 _primary_5lm5p_10 _mini_5lm5p_55 _plain_5lm5p_10 ml-1" data-testid="clinical-document-card__phase" style="background:;color:;">
         <!--[-->
         <span class="">
          Phase 1
         </span>
         <!--]-->
        </span>
        <!-- -->
       </div>
       <!--]-->
      </div>
      <div class="mt-2 flex items-start">
       <div class="flex-1 overflow-hidden">
        <div class="flex">
         <div>
          <div class="_title_afoc1_6">
           <!--[-->
           <div class="inline-flex max-w-full">
            <div class="_tipsContainer_b7pjb_1 _normal_b7pjb_23" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
             <!--[-->
             <!--]-->
             <!-- -->
             <!--[-->
             <!--[-->
             <span class="_title_1rpuv_1" data-testid="clinical-document-card__title">
              A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Clinical Activity of Itolizumab in Subjects With Acute Respiratory Distress Syndrome Caused by Infectious Pneumonia
             </span>
             <!--]-->
             <!--]-->
            </div>
           </div>
           <!--]-->
          </div>
          <!--[-->
          <!--]-->
         </div>
         <!-- -->
        </div>
        <div class="_content_afoc1_31">
         <!--[-->
         <!-- -->
         <div>
          <div class="_container_16a6u_1 _containerStyle_16a6u_7 hidden md:block" style="--374e759f:60px;--661d8904:#1976d2;--470d35e6:20px;--78a7937a:20px;--cab18e14:#1976d2;--324c64a8:#1976d2;--8277a0b4:0px;">
           <div>
            <!--[-->
            <div>
             To evaluate the safety, tolerability, PK, PD, and clinical activity of Itolizumab in subjects with acute respiratory distress syndrome (ARDS) caused by Infectious Pneumonia.
            </div>
            <!--]-->
           </div>
           <!-- -->
          </div>
          <!-- -->
          <div class="ant-descriptions ant-descriptions-small _small_l74zf_21 _horizontal_l74zf_18 mt-2 hidden md:block">
           <!-- -->
           <div class="ant-descriptions-view">
            <table>
             <tbody>
              <!--[-->
              <tr class="ant-descriptions-row">
               <!--[-->
               <td class="ant-descriptions-item" colspan="1" style="">
                <div class="ant-descriptions-item-container">
                 <span class="ant-descriptions-item-label" style="width:auto;">
                  <!--[-->
                  <span class="_label_l74zf_1" data-testid="descriptions-item__label--startDate">
                   Start Date
                  </span>
                  <!--]-->
                 </span>
                 <span class="ant-descriptions-item-content" style="max-width:100%;">
                  <!--[-->
                  <span class="_content_l74zf_6" data-testid="descriptions-item__value--startDate">
                   <!--[-->
                   <span class="text-grey-1100" data-testid="clinical-document-card__start-date">
                    31 Dec 2023
                   </span>
                   <!--]-->
                  </span>
                  <!--]-->
                 </span>
                </div>
               </td>
               <!--]-->
              </tr>
              <tr class="ant-descriptions-row">
               <!--[-->
               <td class="ant-descriptions-item" colspan="1" style="">
                <div class="ant-descriptions-item-container">
                 <span class="ant-descriptions-item-label" style="width:auto;">
                  <!--[-->
                  <span class="_label_l74zf_1" data-testid="descriptions-item__label--sponsor">
                   Sponsor / Collaborator
                  </span>
                  <!--]-->
                 </span>
                 <span class="ant-descriptions-item-content" style="max-width:100%;">
                  <!--[-->
                  <span class="_content_l74zf_6" data-testid="descriptions-item__value--sponsor">
                   <!--[-->
                   <span style="--bdf8c0bc:14px;">
                    <!--[-->
                    <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
                     <!--[-->
                     <!--[-->
                     <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--organization" style="background:;color:;">
                      <!--[-->
                      <span class="mr-1 h-5 w-5 flex-shrink-0">
                       <!--[-->
                       <span class="_avatar_3wddt_11 ant-avatar ant-avatar-square ant-avatar-image" data-testid="ui-avatar" style="width:20px;height:20px;line-height:20px;font-size:18px;">
                        <img alt="Biotech Pharmaceutical Co., Ltd." src="https://filecdn.shuidi.cn/img/upload/images_logo/52/1e/87/521e87a84dd787a4e7efbd01b59d0b3e.png/0x0.png"/>
                       </span>
                       <!--]-->
                      </span>
                      <a class="flex-1 truncate text-black" href="/organization/6e991247a81c0bd7242a0c14895f4963" rel="noopener" target="_blank">
                       <!--[-->
                       <!--[-->
                       Biotech Pharmaceutical Co., Ltd.
                       <!--]-->
                       <!--]-->
                      </a>
                      <!-- -->
                      <!-- -->
                      <!--]-->
                     </span>
                     <!--]-->
                     <!--]-->
                     <!-- -->
                    </div>
                    <!--]-->
                   </span>
                   <!--]-->
                  </span>
                  <!--]-->
                 </span>
                </div>
               </td>
               <!--]-->
              </tr>
              <!--]-->
             </tbody>
            </table>
           </div>
          </div>
         </div>
         <!--]-->
        </div>
       </div>
      </div>
     </div>
     <!--]-->
    </div>
    <div class="_container_8x5ka_1 _clinicalCard_1rpuv_1 mt-3" data-testid="clinical-document-card">
     <!-- -->
     <!--[-->
     <div class="_container_afoc1_1 border">
      <div class="_subTitle_afoc1_14">
       <!--[-->
       <div class="flex flex-wrap items-center justify-start">
        <div class="inline-flex max-w-full">
         <div class="_tipsContainer_b7pjb_1 _normal_b7pjb_23" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
          <!--[-->
          <!--]-->
          <!-- -->
          <!--[-->
          <!--[-->
          <span class="text-green-500" data-testid="clinical-document-card__register-number">
           NCT05986162
          </span>
          <!--]-->
          <!--]-->
         </div>
        </div>
        <span class="mx-1 text-grey-450">
         /
        </span>
        <span class="_tag_5lm5p_1 _default_5lm5p_20 _mini_5lm5p_55" data-testid="clinical-study-status" style="background:#FAECDA;color:#A85604;">
         <!--[-->
         <span class="">
          Not yet recruiting
         </span>
         <!--]-->
        </span>
        <span class="_tag_5lm5p_1 _primary_5lm5p_10 _mini_5lm5p_55 _plain_5lm5p_10 ml-1" data-testid="clinical-document-card__phase" style="background:;color:;">
         <!--[-->
         <span class="">
          Phase 1
         </span>
         <!--]-->
        </span>
        <!-- -->
       </div>
       <!--]-->
      </div>
      <div class="mt-2 flex items-start">
       <div class="flex-1 overflow-hidden">
        <div class="flex">
         <div>
          <div class="_title_afoc1_6">
           <!--[-->
           <div class="inline-flex max-w-full">
            <div class="_tipsContainer_b7pjb_1 _normal_b7pjb_23" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
             <!--[-->
             <!--]-->
             <!-- -->
             <!--[-->
             <!--[-->
             <span class="_title_1rpuv_1" data-testid="clinical-document-card__title">
              A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Clinical Activity of Itolizumab in Subjects With Dermatomyositis
             </span>
             <!--]-->
             <!--]-->
            </div>
           </div>
           <!--]-->
          </div>
          <!--[-->
          <!--]-->
         </div>
         <!-- -->
        </div>
        <div class="_content_afoc1_31">
         <!--[-->
         <!-- -->
         <div>
          <div class="_container_16a6u_1 _containerStyle_16a6u_7 hidden md:block" style="--374e759f:60px;--661d8904:#1976d2;--470d35e6:20px;--78a7937a:20px;--cab18e14:#1976d2;--324c64a8:#1976d2;--8277a0b4:0px;">
           <div>
            <!--[-->
            <div>
             To evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of Itolizumab in subjects with Dermatomyositis.
            </div>
            <!--]-->
           </div>
           <!-- -->
          </div>
          <!-- -->
          <div class="ant-descriptions ant-descriptions-small _small_l74zf_21 _horizontal_l74zf_18 mt-2 hidden md:block">
           <!-- -->
           <div class="ant-descriptions-view">
            <table>
             <tbody>
              <!--[-->
              <tr class="ant-descriptions-row">
               <!--[-->
               <td class="ant-descriptions-item" colspan="1" style="">
                <div class="ant-descriptions-item-container">
                 <span class="ant-descriptions-item-label" style="width:auto;">
                  <!--[-->
                  <span class="_label_l74zf_1" data-testid="descriptions-item__label--startDate">
                   Start Date
                  </span>
                  <!--]-->
                 </span>
                 <span class="ant-descriptions-item-content" style="max-width:100%;">
                  <!--[-->
                  <span class="_content_l74zf_6" data-testid="descriptions-item__value--startDate">
                   <!--[-->
                   <span class="text-grey-1100" data-testid="clinical-document-card__start-date">
                    30 Dec 2023
                   </span>
                   <!--]-->
                  </span>
                  <!--]-->
                 </span>
                </div>
               </td>
               <!--]-->
              </tr>
              <tr class="ant-descriptions-row">
               <!--[-->
               <td class="ant-descriptions-item" colspan="1" style="">
                <div class="ant-descriptions-item-container">
                 <span class="ant-descriptions-item-label" style="width:auto;">
                  <!--[-->
                  <span class="_label_l74zf_1" data-testid="descriptions-item__label--sponsor">
                   Sponsor / Collaborator
                  </span>
                  <!--]-->
                 </span>
                 <span class="ant-descriptions-item-content" style="max-width:100%;">
                  <!--[-->
                  <span class="_content_l74zf_6" data-testid="descriptions-item__value--sponsor">
                   <!--[-->
                   <span style="--bdf8c0bc:14px;">
                    <!--[-->
                    <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
                     <!--[-->
                     <!--[-->
                     <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--organization" style="background:;color:;">
                      <!--[-->
                      <span class="mr-1 h-5 w-5 flex-shrink-0">
                       <!--[-->
                       <span class="_avatar_3wddt_11 ant-avatar ant-avatar-square ant-avatar-image" data-testid="ui-avatar" style="width:20px;height:20px;line-height:20px;font-size:18px;">
                        <img alt="Biotech Pharmaceutical Co., Ltd." src="https://filecdn.shuidi.cn/img/upload/images_logo/52/1e/87/521e87a84dd787a4e7efbd01b59d0b3e.png/0x0.png"/>
                       </span>
                       <!--]-->
                      </span>
                      <a class="flex-1 truncate text-black" href="/organization/6e991247a81c0bd7242a0c14895f4963" rel="noopener" target="_blank">
                       <!--[-->
                       <!--[-->
                       Biotech Pharmaceutical Co., Ltd.
                       <!--]-->
                       <!--]-->
                      </a>
                      <!-- -->
                      <!-- -->
                      <!--]-->
                     </span>
                     <!--]-->
                     <!--]-->
                     <!-- -->
                    </div>
                    <!--]-->
                   </span>
                   <!--]-->
                  </span>
                  <!--]-->
                 </span>
                </div>
               </td>
               <!--]-->
              </tr>
              <!--]-->
             </tbody>
            </table>
           </div>
          </div>
         </div>
         <!--]-->
        </div>
       </div>
      </div>
     </div>
     <!--]-->
    </div>
    <div class="_container_8x5ka_1 _clinicalCard_1rpuv_1 mt-3" data-testid="clinical-document-card">
     <!-- -->
     <!--[-->
     <div class="_container_afoc1_1 border">
      <div class="_subTitle_afoc1_14">
       <!--[-->
       <div class="flex flex-wrap items-center justify-start">
        <div class="inline-flex max-w-full">
         <div class="_tipsContainer_b7pjb_1 _normal_b7pjb_23" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
          <!--[-->
          <!--]-->
          <!-- -->
          <!--[-->
          <!--[-->
          <span class="text-green-500" data-testid="clinical-document-card__register-number">
           CTR20230436
          </span>
          <!--]-->
          <!--]-->
         </div>
        </div>
        <span class="mx-1 text-grey-450">
         /
        </span>
        <span class="_tag_5lm5p_1 _default_5lm5p_20 _mini_5lm5p_55" data-testid="clinical-study-status" style="background:#FCEDEF;color:#D11A32;">
         <!--[-->
         <span class="">
          Suspended
         </span>
         <!--]-->
        </span>
        <span class="_tag_5lm5p_1 _primary_5lm5p_10 _mini_5lm5p_55 _plain_5lm5p_10 ml-1" data-testid="clinical-document-card__phase" style="background:;color:;">
         <!--[-->
         <span class="">
          Phase 1
         </span>
         <!--]-->
        </span>
        <!-- -->
       </div>
       <!--]-->
      </div>
      <div class="mt-2 flex items-start">
       <div class="flex-1 overflow-hidden">
        <div class="flex">
         <div>
          <div class="_title_afoc1_6">
           <!--[-->
           <div class="inline-flex max-w-full">
            <div class="_tipsContainer_b7pjb_1 _normal_b7pjb_23" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
             <!--[-->
             <!--]-->
             <!-- -->
             <!--[-->
             <!--[-->
             <span class="_title_1rpuv_1" data-testid="clinical-document-card__title">
              伊立珠单抗注射液在急性移植物抗宿主病（aGVHD）受试者中的安全性、耐受性、药代动力学、药效学和疗效的Ⅰ期临床试验
             </span>
             <!--]-->
             <!--]-->
            </div>
           </div>
           <!--]-->
          </div>
          <!--[-->
          <!--]-->
         </div>
         <!-- -->
        </div>
        <div class="_content_afoc1_31">
         <!--[-->
         <div class="my-2 flex rounded bg-grey-20 p-[10px]">
          <span class="mr-1 flex-shrink-0 text-grey-1100">
           [Translation]
          </span>
          <span class="line-clamp-3">
           A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of irizumab injection in subjects with acute graft-versus-host disease (aGVHD)
          </span>
         </div>
         <div>
          <div class="_container_16a6u_1 _containerStyle_16a6u_7 hidden md:block" style="--374e759f:60px;--661d8904:#1976d2;--470d35e6:20px;--78a7937a:20px;--cab18e14:#1976d2;--324c64a8:#1976d2;--8277a0b4:0px;">
           <div>
            <!--[-->
            <div>
             主要目的：评价伊立珠单抗注射液单次给药、多次给药治疗急性移植物抗宿主病（aGVHD）的安全性和耐受性，并确定伊立珠单抗注射液治疗aGVHD的最佳剂量。
次要目的：1.评价伊立珠单抗注射液在aGVHD受试者中单次和多次给药的药代动力学特征、药效学特征和免疫原性。
2.评价伊立珠单抗注射液治疗aGVHD的临床效果。
            </div>
            <!--]-->
           </div>
           <!-- -->
          </div>
          <div class="mt-2 hidden rounded bg-grey-20 p-[10px] md:flex">
           <span class="mr-1 flex-shrink-0 text-grey-1100">
            [Translation]
           </span>
           <div class="line-clamp-3">
            Primary objective: To evaluate the safety and tolerability of single and multiple administrations of irizumab injection in the treatment of acute graft-versus-host disease (aGVHD), and to determine the optimal dose of irizumab injection in the treatment of aGVHD.
Secondary objectives: 1. To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics and immunogenicity of single and multiple administrations of irizumab injection in subjects with aGVHD.
2. To evaluate the clinical effect of irizumab injection in the treatment of aGVHD.
           </div>
          </div>
          <div class="ant-descriptions ant-descriptions-small _small_l74zf_21 _horizontal_l74zf_18 mt-2 hidden md:block">
           <!-- -->
           <div class="ant-descriptions-view">
            <table>
             <tbody>
              <!--[-->
              <tr class="ant-descriptions-row">
               <!--[-->
               <td class="ant-descriptions-item" colspan="1" style="">
                <div class="ant-descriptions-item-container">
                 <span class="ant-descriptions-item-label" style="width:auto;">
                  <!--[-->
                  <span class="_label_l74zf_1" data-testid="descriptions-item__label--startDate">
                   Start Date
                  </span>
                  <!--]-->
                 </span>
                 <span class="ant-descriptions-item-content" style="max-width:100%;">
                  <!--[-->
                  <span class="_content_l74zf_6" data-testid="descriptions-item__value--startDate">
                   <!--[-->
                   <span class="text-grey-1100" data-testid="clinical-document-card__start-date">
                    28 Aug 2023
                   </span>
                   <!--]-->
                  </span>
                  <!--]-->
                 </span>
                </div>
               </td>
               <!--]-->
              </tr>
              <tr class="ant-descriptions-row">
               <!--[-->
               <td class="ant-descriptions-item" colspan="1" style="">
                <div class="ant-descriptions-item-container">
                 <span class="ant-descriptions-item-label" style="width:auto;">
                  <!--[-->
                  <span class="_label_l74zf_1" data-testid="descriptions-item__label--sponsor">
                   Sponsor / Collaborator
                  </span>
                  <!--]-->
                 </span>
                 <span class="ant-descriptions-item-content" style="max-width:100%;">
                  <!--[-->
                  <span class="_content_l74zf_6" data-testid="descriptions-item__value--sponsor">
                   <!--[-->
                   <span style="--bdf8c0bc:14px;">
                    <!--[-->
                    <div class="flex items-center overflow-hidden flex-wrap gap-x-1 gap-y-1">
                     <!--[-->
                     <!--[-->
                     <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 _entityTag_3wddt_1" data-testid="entity-tag--organization" style="background:;color:;">
                      <!--[-->
                      <span class="mr-1 h-5 w-5 flex-shrink-0">
                       <!--[-->
                       <span class="_avatar_3wddt_11 ant-avatar ant-avatar-square ant-avatar-image" data-testid="ui-avatar" style="width:20px;height:20px;line-height:20px;font-size:18px;">
                        <img alt="Biotech Pharmaceutical Co., Ltd." src="https://filecdn.shuidi.cn/img/upload/images_logo/52/1e/87/521e87a84dd787a4e7efbd01b59d0b3e.png/0x0.png"/>
                       </span>
                       <!--]-->
                      </span>
                      <a class="flex-1 truncate text-black" href="/organization/6e991247a81c0bd7242a0c14895f4963" rel="noopener" target="_blank">
                       <!--[-->
                       <!--[-->
                       Biotech Pharmaceutical Co., Ltd.
                       <!--]-->
                       <!--]-->
                      </a>
                      <!-- -->
                      <!-- -->
                      <!--]-->
                     </span>
                     <!--]-->
                     <!--]-->
                     <!-- -->
                    </div>
                    <!--]-->
                   </span>
                   <!--]-->
                  </span>
                  <!--]-->
                 </span>
                </div>
               </td>
               <!--]-->
              </tr>
              <!--]-->
             </tbody>
            </table>
           </div>
          </div>
         </div>
         <!--]-->
        </div>
       </div>
      </div>
     </div>
     <!--]-->
    </div>
    <!--]-->
   </div>
   <div class="mt-10 md:mt-12">
    <div class="mb-4 break-all text-sm text-black">
     <!--[-->
     <span class="_mosaic_dzucl_1">
      <!--[-->
      <span class="font-semibold text-seo-blue-500 underline">
       100
      </span>
      <!--]-->
     </span>
     <!--]-->
     <span>
      Clinical Results associated with Itolizumab
     </span>
    </div>
    <div class="inline-flex max-w-full mt-4 w-full">
     <div class="_tipsContainer_b7pjb_1 _yellow_b7pjb_30 _tipsBorder_b7pjb_9" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
      <!--[-->
      <!--]-->
      <svg class="h-4 w-[10px]" fill="currentColor" height="1.2em" viewbox="0 0 10 16" width="1.2em">
       <path d="M9.70678 6.27142H5.92999L6.67408 0.15021C6.68107 0.0907286 6.65118 0.0334335 6.60111 0.0103023C6.55104 -0.0128288 6.49315 0.00392205 6.45976 0.0512057L0.0610803 9.20641C-0.00721034 9.30424 -0.0192403 9.43647 0.0300607 9.54737C0.0793617 9.65827 0.181418 9.72854 0.293217 9.72858H4.07001L3.32592 15.8498C3.31893 15.9093 3.34882 15.9666 3.39889 15.9897C3.44896 16.0128 3.50685 15.9961 3.54024 15.9488L9.93892 6.79359C10.0072 6.69576 10.0192 6.56353 9.96994 6.45263C9.92064 6.34174 9.81858 6.27146 9.70678 6.27142Z" fill-rule="evenodd">
       </path>
      </svg>
      <!--[-->
      <span class="_text_b7pjb_17">
       Login to view more data
      </span>
      <!--]-->
     </div>
    </div>
   </div>
   <div class="mt-10 md:mt-12">
    <div class="mb-4 break-all text-sm text-black">
     <!--[-->
     <span class="_mosaic_dzucl_1">
      <!--[-->
      <span class="font-semibold text-seo-blue-500 underline">
       100
      </span>
      <!--]-->
     </span>
     <!--]-->
     <span>
      Translational Medicine associated with Itolizumab
     </span>
    </div>
    <div class="inline-flex max-w-full mt-4 w-full">
     <div class="_tipsContainer_b7pjb_1 _yellow_b7pjb_30 _tipsBorder_b7pjb_9" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
      <!--[-->
      <!--]-->
      <svg class="h-4 w-[10px]" fill="currentColor" height="1.2em" viewbox="0 0 10 16" width="1.2em">
       <path d="M9.70678 6.27142H5.92999L6.67408 0.15021C6.68107 0.0907286 6.65118 0.0334335 6.60111 0.0103023C6.55104 -0.0128288 6.49315 0.00392205 6.45976 0.0512057L0.0610803 9.20641C-0.00721034 9.30424 -0.0192403 9.43647 0.0300607 9.54737C0.0793617 9.65827 0.181418 9.72854 0.293217 9.72858H4.07001L3.32592 15.8498C3.31893 15.9093 3.34882 15.9666 3.39889 15.9897C3.44896 16.0128 3.50685 15.9961 3.54024 15.9488L9.93892 6.79359C10.0072 6.69576 10.0192 6.56353 9.96994 6.45263C9.92064 6.34174 9.81858 6.27146 9.70678 6.27142Z" fill-rule="evenodd">
       </path>
      </svg>
      <!--[-->
      <span class="_text_b7pjb_17">
       Login to view more data
      </span>
      <!--]-->
     </div>
    </div>
   </div>
   <div class="mt-10 md:mt-12">
    <div class="mb-4 break-all text-sm text-black">
     <!--[-->
     <span class="_mosaic_dzucl_1">
      <!--[-->
      <span class="font-semibold text-seo-blue-500 underline">
       100
      </span>
      <!--]-->
     </span>
     <!--]-->
     <span>
      Patents (Medical) associated with Itolizumab
     </span>
    </div>
    <div class="inline-flex max-w-full mt-4 w-full">
     <div class="_tipsContainer_b7pjb_1 _yellow_b7pjb_30 _tipsBorder_b7pjb_9" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
      <!--[-->
      <!--]-->
      <svg class="h-4 w-[10px]" fill="currentColor" height="1.2em" viewbox="0 0 10 16" width="1.2em">
       <path d="M9.70678 6.27142H5.92999L6.67408 0.15021C6.68107 0.0907286 6.65118 0.0334335 6.60111 0.0103023C6.55104 -0.0128288 6.49315 0.00392205 6.45976 0.0512057L0.0610803 9.20641C-0.00721034 9.30424 -0.0192403 9.43647 0.0300607 9.54737C0.0793617 9.65827 0.181418 9.72854 0.293217 9.72858H4.07001L3.32592 15.8498C3.31893 15.9093 3.34882 15.9666 3.39889 15.9897C3.44896 16.0128 3.50685 15.9961 3.54024 15.9488L9.93892 6.79359C10.0072 6.69576 10.0192 6.56353 9.96994 6.45263C9.92064 6.34174 9.81858 6.27146 9.70678 6.27142Z" fill-rule="evenodd">
       </path>
      </svg>
      <!--[-->
      <span class="_text_b7pjb_17">
       Login to view more data
      </span>
      <!--]-->
     </div>
    </div>
   </div>
   <div class="mt-10 md:mt-12">
    <div class="mb-4 break-all text-sm text-black">
     <div class="inline-flex max-w-full">
      <!--[-->
      <span class="cursor-pointer font-semibold text-seo-blue-500 underline" data-testid="related-paper-count">
       117
      </span>
      <!--]-->
     </div>
     <span>
      Literatures (Medical) associated with Itolizumab
     </span>
    </div>
    <!--[-->
    <div class="_container_8x5ka_1 _literatureCard_nf4fx_1" data-testid="literature-document-card">
     <!-- -->
     <!--[-->
     <div class="_container_afoc1_1 border">
      <div class="_subTitle_afoc1_14">
       <!--[-->
       <div class="flex flex-col flex-wrap md:flex-row md:items-center md:justify-start">
        <span data-testid="literature-document-card__publication-data">
         01 Dec 2024
        </span>
        <span class="mx-1 hidden md:block">
         ·
        </span>
        <span class="mr-2 text-black" data-testid="literature-document-card__journal-name">
         Current Hematologic Malignancy Reports
        </span>
        <!-- -->
       </div>
       <!--]-->
      </div>
      <div class="mt-2 flex items-start">
       <div class="flex-1 overflow-hidden">
        <div class="flex">
         <div>
          <div class="_title_afoc1_6">
           <!--[-->
           <div class="inline-flex max-w-full">
            <div class="_tipsContainer_b7pjb_1 _normal_b7pjb_23" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
             <!--[-->
             <!--]-->
             <!-- -->
             <!--[-->
             <!--[-->
             <span class="_title_nf4fx_1" data-testid="literature-document-card__title">
              Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease
             </span>
             <!--]-->
             <!--]-->
            </div>
           </div>
           <!--]-->
          </div>
          <!--[-->
          <!--]-->
         </div>
         <!-- -->
        </div>
        <div class="_content_afoc1_31">
         <!--[-->
         <div class="md:hidden">
          <!-- -->
         </div>
         <div class="hidden md:block">
          <div class="flex">
           <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 mr-2" style="background:#EDF8FF;color:#0170BD;">
            <!--[-->
            Review
            <!--]-->
           </span>
           <!-- -->
          </div>
          <div class="mt-3 line-clamp-3" data-testid="literature-document-card__author">
           Author:
           <!--[-->
           <span>
            Hamadani, Mehdi
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Abedin, Sameem
            <!-- -->
           </span>
           <!--]-->
          </div>
          <div class="_container_16a6u_1 _containerStyle_16a6u_7 mt-3" data-testid="literature-document-card__abstract" style="--374e759f:100px;--661d8904:#1976d2;--470d35e6:20px;--78a7937a:20px;--cab18e14:#1976d2;--324c64a8:#1976d2;--8277a0b4:0px;">
           <div>
            <!--[-->
            <!--[-->
            <div class="text-text-t2 whitespace-pre-wrap break-words text-sm leading-5">
             <span class="float-left mr-1">
             </span>
             <div class="text-black-default text-sm" style="word-break:break-word;">
              <jats:sec>
               <jats:title>
                PURPOSE OF REVIEW
               </jats:title>
               <jats:p>
                Graft-versus-host disease (GVHD) is a serious complication after allogeneic HCT. Recently, several pivotal studies have been conducted demonstrating significant improvements in the management of GVHD. Here, we review important trials pertaining to GVHD prevention, acute GVHD treatment, and treatment of steroid refractory acute and chronic GVHD.
               </jats:p>
              </jats:sec>
              <jats:sec>
               <jats:title>
                RECENT FINDINGS
               </jats:title>
               <jats:p>
                Clinical trials in preventing GVHD demonstrate lower rates of severe acute GVHD and chronic GVHD with post-transplant cyclophosphamide. For acute GVHD, lower risk acute GVHD appears amenable to steroid-sparing therapies, such as sirolimus and itacitinib. Combinations with novel agents such as itolizumab appear promising for high risk acute GVHD. For steroid-refractory acute GVHD, ruxolitinib should be considered first line therapy. For chronic GVHD requiring therapy beyond steroids, ruxolitinib, belumosudil, and ibrutinib are now available and should be considered. Increasingly, GVHD has become a manageable complication after allogeneic HCT potentially translating to greater success with allogeneic HCT in the future.
               </jats:p>
              </jats:sec>
             </div>
            </div>
            <!--]-->
            <!--]-->
           </div>
           <!-- -->
          </div>
         </div>
         <!--]-->
        </div>
       </div>
      </div>
     </div>
     <!--]-->
    </div>
    <div class="_container_8x5ka_1 _literatureCard_nf4fx_1 mt-3" data-testid="literature-document-card">
     <!-- -->
     <!--[-->
     <div class="_container_afoc1_1 border">
      <div class="_subTitle_afoc1_14">
       <!--[-->
       <div class="flex flex-col flex-wrap md:flex-row md:items-center md:justify-start">
        <span data-testid="literature-document-card__publication-data">
         30 Nov 2024
        </span>
        <span class="mx-1 hidden md:block">
         ·
        </span>
        <span class="mr-2 text-black" data-testid="literature-document-card__journal-name">
         Acute and Critical Care
        </span>
        <!-- -->
       </div>
       <!--]-->
      </div>
      <div class="mt-2 flex items-start">
       <div class="flex-1 overflow-hidden">
        <div class="flex">
         <div>
          <div class="_title_afoc1_6">
           <!--[-->
           <div class="inline-flex max-w-full">
            <div class="_tipsContainer_b7pjb_1 _normal_b7pjb_23" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
             <!--[-->
             <!--]-->
             <!-- -->
             <!--[-->
             <!--[-->
             <span class="_title_nf4fx_1" data-testid="literature-document-card__title">
              Corrigendum to: Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
             </span>
             <!--]-->
             <!--]-->
            </div>
           </div>
           <!--]-->
          </div>
          <!--[-->
          <!--]-->
         </div>
         <!-- -->
        </div>
        <div class="_content_afoc1_31">
         <!--[-->
         <div class="md:hidden">
          <!-- -->
         </div>
         <div class="hidden md:block">
          <div class="flex">
           <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 mr-2" style="background:#EDF8FF;color:#0170BD;">
            <!--[-->
            Article
            <!--]-->
           </span>
           <!-- -->
          </div>
          <div class="mt-3 line-clamp-3" data-testid="literature-document-card__author">
           Author:
           <!--[-->
           <span>
            Pattanayak, Arunima
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Das, Rekha
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Kumar, Ajeet
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Nagaraju, Pradhan Manigowdanahundi
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Palavesam, Saravanan
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Kumar, Neeraj
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Kumar, Abhyuday
            <!-- -->
           </span>
           <!--]-->
          </div>
          <!-- -->
         </div>
         <!--]-->
        </div>
       </div>
      </div>
     </div>
     <!--]-->
    </div>
    <div class="_container_8x5ka_1 _literatureCard_nf4fx_1 mt-3" data-testid="literature-document-card">
     <!-- -->
     <!--[-->
     <div class="_container_afoc1_1 border">
      <div class="_subTitle_afoc1_14">
       <!--[-->
       <div class="flex flex-col flex-wrap md:flex-row md:items-center md:justify-start">
        <span data-testid="literature-document-card__publication-data">
         01 Sep 2024
        </span>
        <span class="mx-1 hidden md:block">
         ·
        </span>
        <span class="mr-2 text-black" data-testid="literature-document-card__journal-name">
         Journal of Environmental Quality
        </span>
        <!-- -->
       </div>
       <!--]-->
      </div>
      <div class="mt-2 flex items-start">
       <div class="flex-1 overflow-hidden">
        <div class="flex">
         <div>
          <div class="_title_afoc1_6">
           <!--[-->
           <div class="inline-flex max-w-full">
            <div class="_tipsContainer_b7pjb_1 _normal_b7pjb_23" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
             <!--[-->
             <!--]-->
             <!-- -->
             <!--[-->
             <!--[-->
             <span class="_title_nf4fx_1" data-testid="literature-document-card__title">
              High‐density polyethylene microplastics in agricultural soil: Impact on microbes, enzymes, and carbon‐nitrogen ratio
             </span>
             <!--]-->
             <!--]-->
            </div>
           </div>
           <!--]-->
          </div>
          <!--[-->
          <!--]-->
         </div>
         <!-- -->
        </div>
        <div class="_content_afoc1_31">
         <!--[-->
         <div class="md:hidden">
          <!-- -->
         </div>
         <div class="hidden md:block">
          <div class="flex">
           <span class="_tag_5lm5p_1 _default_5lm5p_20 _small_5lm5p_31 mr-2" style="background:#EDF8FF;color:#0170BD;">
            <!--[-->
            Article
            <!--]-->
           </span>
           <!-- -->
          </div>
          <div class="mt-3 line-clamp-3" data-testid="literature-document-card__author">
           Author:
           <!--[-->
           <span>
            Behera, Binayak Prasad
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Patnaik, Aliva
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Mishra, C. S. K.
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Moharana, Tanushree
            <span class="mr-1">
             ;
            </span>
           </span>
           <span>
            Samal, Rashmi Rekha
            <!-- -->
           </span>
           <!--]-->
          </div>
          <div class="_container_16a6u_1 _containerStyle_16a6u_7 mt-3" data-testid="literature-document-card__abstract" style="--374e759f:100px;--661d8904:#1976d2;--470d35e6:20px;--78a7937a:20px;--cab18e14:#1976d2;--324c64a8:#1976d2;--8277a0b4:0px;">
           <div>
            <!--[-->
            <!--[-->
            <div class="text-text-t2 whitespace-pre-wrap break-words text-sm leading-5">
             <span class="float-left mr-1">
             </span>
             <div class="text-black-default text-sm" style="word-break:break-word;">
              <jats:title>
               Abstract
              </jats:title>
              <jats:p>
               Microplastics (MPs), recognized as emerging pollutants, pose a significant threat to diverse organisms and have adverse effects on agricultural soil. High‐density polyethylene (HDPE) holds a prominent position among prevalent forms of MPs. In the current investigations, the impact of HDPE was assessed at four different concentrations (0.25%, 0.5%, 0.75%, and 1.0%) on agricultural soil, microbial population, exoenzymes activities including amylase, cellulase, and invertase, and alteration in carbon‐to‐nitrogen (C/N) ratio. Both bacterial and fungal populations exhibited a non‐concentration‐dependent response to different concentrations of HDPE over time. In this study, we refer to the concentrations of 0.25%, 0.5%, 0.75%, and 1.0% as HT1, HT2, HT3, and HT4, respectively. Initial MP application significantly reduced bacterial colony counts for HT1, HT2, and HT4, while HT3 showed no significant change. On the 60th day, HT1 and HT3 exhibited a higher bacterial colony count compared to the control. On the other hand, fungal populations increased to maximum on day 1 but displayed no distinct time‐dependent trend from days 15 to 60. Furthermore, enzyme activities decreased with increasing concentrations of MPs over an extended period. Molecular docking studies suggest that HDPE can hinder enzyme activity by forming hydrogen bonds with enzymes. The C/N ratio was found to be significantly higher in MP‐treated soils on the 60th day relative to control, suggesting relatively slower degradation of carbon compounds in the MP‐treated soils.
              </jats:p>
             </div>
            </div>
            <!--]-->
            <!--]-->
           </div>
           <!-- -->
          </div>
         </div>
         <!--]-->
        </div>
       </div>
      </div>
     </div>
     <!--]-->
    </div>
    <!--]-->
   </div>
   <div class="mt-10 md:mt-12">
    <div class="mb-4 break-all text-sm text-black">
     <div class="inline-flex max-w-full">
      <!--[-->
      <span class="cursor-pointer font-semibold text-seo-blue-500 underline" data-testid="related-news-count">
       83
      </span>
      <!--]-->
     </div>
     <span>
      News (Medical) associated with Itolizumab
     </span>
    </div>
    <!--[-->
    <div class="_container_8x5ka_1 _newsCard_1m6m5_1" data-testid="news-document-card">
     <!-- -->
     <!--[-->
     <div class="_container_afoc1_1 border">
      <div class="_subTitle_afoc1_14">
       <!--[-->
       <span class="">
        17 Feb 2025
       </span>
       <div class="hidden md:inline-block">
        <span class="px-1">
         ·
        </span>
        <a class="text-blue-500" href="https://www.biospace.com/drug-development/i-i-investment-ramps-up-with-novel-targets-and-boundless-opportunity" rel="nofollow noopener" target="_blank">
         <!--[-->
         www.biospace.com
         <!--]-->
        </a>
       </div>
       <!--]-->
      </div>
      <div class="mt-2 flex items-start">
       <div class="flex-1 overflow-hidden">
        <div class="flex">
         <div>
          <div class="_title_afoc1_6">
           <!--[-->
           <a data-testid="news-document-card__title" href="https://www.biospace.com/drug-development/i-i-investment-ramps-up-with-novel-targets-and-boundless-opportunity" rel="noopener" target="_blank">
            <!--[-->
            <span class="_title_1m6m5_1">
             I&amp;I Investment Ramps Up With Novel Targets and Boundless Opportunity
            </span>
            <!--]-->
           </a>
           <!--]-->
          </div>
          <!--[-->
          <div class="_container_16a6u_1 _containerStyle_16a6u_7 mt-2 hidden text-sm text-grey-450 md:block" style="--374e759f:60px;--661d8904:#1976d2;--470d35e6:20px;--78a7937a:20px;--cab18e14:#1976d2;--324c64a8:#1976d2;--8277a0b4:0px;">
           <div>
            <!--[-->
            <div data-testid="news-document-card__content" style="word-break:break-word;">
             iStock, 
z_wei
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and more. 
One of biopharma’s hottest therapeutic areas, immunology and inflammation has seen an uptick in 
M&amp;A activity
 in recent years, with big names like Sanofi and Gilead dropping billions of dollars to expand their I&amp;I pipelines. At the same time, the space is seeing an influx of new companies, including 
Bambusa Therapeutics
, which launched Friday with $90 million in series A funds. 
Momentum in this space was sparked at the turn of the century by the 
arrival
 of therapeutic antibodies. After winning FDA approval in 2002, Abbvie’s Humira—the first tumor necrosis factor (TNF) inhibitor—became one of the best-selling drugs of all time, generating over 
$200 billion
 in lifetime sales to patients with rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn’s disease and more.
Over 20 years later, with Humira and other key medicines having lost their exclusivity and research providing a better understanding of the biology underlying the field, it’s time for the next wave of I&amp;I. Indeed, novel targets and modalities are attracting an influx of investment into the I&amp;I space, said Thomas Smith, a senior research analyst covering immunology at Leerink Partners.
“We’re seeing antibodies that are going after targets that have not been targeted before, small molecules that were previously thought to be undruggable,” he told 
BioSpace
. “We’re seeing the emergence of cell therapies.”
And there’s room for them all. The 
second largest
 therapeutic area by value in 2023, the immunology market is 
projected
 to be worth more than $257 billion by 2032.
“[I&amp;I] has large end markets of highly prevalent diseases that, despite having multiple treatment options, still have persistent, high medical need,” Smith said.
M&amp;A Expected to Continue in 2025
The I&amp;I space has made headlines recently for a spate of high-pro In April 2024, Vertex struck 
the biggest deal in biopharma last year
 with its $
4.9 billion buy
 of Alpine Immune Sciences. Then in June, Eli Lilly dropped 
$3.2 billion to acquire
 Morphic Holding. These deals followed Merck’s eyepopping 
$10.8 billion pick-up
 of Prometheus Biosciences a year earlier.
While many big pharma companies already have their own immunology platforms, “innovation does not happen in isolation,” Shaju Backer, global head of immunology at Sanofi, told 
BioSpace 
in an email. This is why his company also complements its in-house R&amp;D with a myriad of strategic partnerships and acquisitions. In 2021, Sanofi 
acquired Kymab
 for $1.4 billion to add an anti-OX40 ligand to its pipeline, hoping to address the underlying disease pathologies of inflammatory diseases like atopic dermatitis without depleting T cells.
More recently, Gilead struck a 
deal
 last month with LEO Pharma worth up to $1.7 billion for its preclinical STAT6 program. Smith expects more of the same in the near future. “We have a lot of reason for thinking this is going to continue to be the case in 2025,” he said.
Pursuit of Novel Targets
TNF blockers like Humira cast a wide net, pulling in some ten indications. Yet patients and practitioners have seen the effects of Humira and other anti-TNF therapies wear off relatively quickly because ancillary pathways take over, according to Backer, making it necessary to target other pathways for disease management and, hopefully, remission.
One of these, the TL1A pathway, plays a key role in driving inflammation and fibrosis in various autoimmune diseases, making its inhibition a promising strategy for multiple indications, including 
inflammatory bowel disease
 (IBD). Merck’s Prometheus buy brought in a potentially best-in-class TL1A inhibitor in late-stage studies for ulcerative colitis and Crohn’s disease. And Sanofi is co-developing a TL1A-targeting antibody, duvakitug, with Teva Pharmaceuticals.
Another target generating a lot of interest is the signal transducer and activator of transcription 6 (STAT6) transcription factor, which is a key regulator of Th2-driven immune response. Indication potential is wide-ranging for STAT6-targeted oral drugs, which could offer an alternative to existing injectable biologics.
Gilead’s recent 
deal
 with LEO Pharma is one example. While the specific indication has not yet been announced, Flavius Martin, executive vice president of research at Gilead, told 
BioSpace
 in an email that the program is “advancing rapidly” toward clinical testing. Elsewhere, Sanofi 
extended
 its collaboration with Nurix Therapeutics last year to include a targeted protein degrader of STAT6.
These are but a few of the many targets now being explored in the I&amp;I space. Others run the gamut from Sanofi’s T cell receptor–targeting amlitelimab for atopic dermatitis, with a 52-week data readout expected in March, to the microRNA-targeting obefazimod from Paris-based biotech Abivax, which is awaiting a Q3 2025 Phase III 
readout
 in ulcerative colitis.
Finally, the “unbridled success” of cell therapies in hematological malignancies is now driving efforts to bring cell therapy to the I&amp;I space, particularly 
for autoimmune disease
, Smith said. Companies like Kyverna are developing CAR T cell therapies to deliver complete B cell depletion that could help reset a patient’s immune system to eliminate the need for chronic treatment. Kyverna is targeting a 2026 
filing
 for its lead therapy KYV-101 in stiff person syndrome, with myasthenia gravis and lupus nephritis to follow.
Meanwhile, Arcellx is taking its cell therapy pipeline from multiple myeloma into autoimmune disease. Last fall, the FDA cleared the company’s Investigational New Drug (IND) application to begin a Phase I trial of its CAR T anito-cell in generalized myasthenia gravis.
If successful, Smith said the biggest challenges to cell therapies for autoimmune indications would be logistics, scalability, reimbursement and identifying the right patients for treatment.
The beauty of the I&amp;I space is that one molecule can have many different applications, Jorge Santos da Silva, CEO of Moonlake Therapeutics, which is developing treatments for inflammatory indications including hidradenitis suppurativa, told 
BioSpace
. “In I&amp;I, you can have these molecules that just walk across a whole lot of therapeutic areas,” a feature he said makes it ripe for investment by biopharma.
Smith agreed. “The end markets for I&amp;I relative to targeted oncology are much broader,” he told 
BioSpace
. “There’s a lot of white space.”
5 I&amp;I Diseases Poised for Disruption in 2025
Thomas Smith, a senior research analyst covering immunology at Leerink Partners, highlighted five indications within the I&amp;I space that he believes could see substantive movement this year.
Editor’s note: Lists of approved products and products in development are not comprehensive.
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
The most severe form of nonalcoholic fatty liver disease, MASH affects 5% to 7% of the global population.
Approved Products
:
Madrigal’s Rezdiffra
In Development
:
Akero Therapeutics’ efruxifermin (Phase III)
Boehringer Ingelheim’s survodutide (Phase III)
Novo Nordisk’s semaglutide (Phase III)
Eli Lilly’s tirzepatide (Phase II)
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD)—including ulcerative colitis (UC) and Crohn’s disease (CD)—affects between 2.4 and 3.1 million people in the U.S.
Approved Products
:
Eli Lilly’s Omvoh
Johnson &amp; Johnson’s Remicade
AbbVie’s Humira
In Development
:
Abivax’s obefazimod for UC (Phase III)
Sanofi and Teva’s duvakitug for UC (Phase II)
Equillium and Biocon’s Itolizumab for UC (Phase II)
Myasthenia Gravis
A chronic autoimmune disorder causing weakness in the voluntary muscles, myasthenia gravis afflicts up to 60,000 people in the U.S.
Approved Products
:
Argenx’s Vyvgart
AstraZeneca’s Ultomiris
UCB’s Rystiggo
In Development
:
Johnson &amp; Johnson’s nipocalimab (under review)
Cabaletta Bio and Kyverna Therapeutics’ CABA-201 (Phase I/II)
COUR Pharmaceuticals’ CNP-106 (Phase II)
Atopic Dermatitis
Atopic dermatitis—a chronic skin condition that causes the skin to become red, itchy and inflamed—affects more than 7% of people in the U.S.
Approved Products:
Sanofi and Regeneron’s Dupixent
Eli Lilly’s Ebglyss
Galderma’s Nemluvio
In Development
:
Sanofi’s amlitelimab (Phase III)
Kymera Therapeutics and Sanofi’s IRAK4 (Phase II)
Apogee Therapeutics’ APG777 (Phase II)
Hidradenitis Suppurativa
Another chronic, inflammatory skin condition, hidradenitis suppurativa afflicts 1% to 4% of the global population.
Approved Products
:
AbbVie’s Humira
Novartis’ Cosentyx
UCB’s Bimzelx
In Development
:
Moonlake Therapeutics’ sonelokimab (Phase III)
Incyte’s povorcitinib (Phase III)
            </div>
            <!--]-->
           </div>
           <!-- -->
          </div>
          <!--]-->
         </div>
         <!-- -->
        </div>
        <div class="_content_afoc1_31">
         <!--[-->
         <div class="inline-flex max-w-full mt-2 flex flex-wrap justify-start">
          <!--[-->
          <div data-testid="news-document-card__tag">
           <!--[-->
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Phase 2
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Phase 3
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Immunotherapy
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Drug Approval
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Acquisition
            <!--]-->
           </span>
           <!--]-->
          </div>
          <!--]-->
         </div>
         <!--]-->
        </div>
       </div>
      </div>
     </div>
     <!--]-->
    </div>
    <div class="_container_8x5ka_1 _newsCard_1m6m5_1 mt-3" data-testid="news-document-card">
     <!-- -->
     <!--[-->
     <div class="_container_afoc1_1 border">
      <div class="_subTitle_afoc1_14">
       <!--[-->
       <span class="">
        07 Feb 2025
       </span>
       <div class="hidden md:inline-block">
        <span class="px-1">
         ·
        </span>
        <a class="text-blue-500" href="https://pipelinereview.com/equillium-announces-positive-data-from-phase-2-study-evaluating-itolizumab-in-patients-with-moderate-to-severe-ulcerative-colitis/" rel="nofollow noopener" target="_blank">
         <!--[-->
         pipelinereview.com
         <!--]-->
        </a>
       </div>
       <!--]-->
      </div>
      <div class="mt-2 flex items-start">
       <div class="flex-1 overflow-hidden">
        <div class="flex">
         <div>
          <div class="_title_afoc1_6">
           <!--[-->
           <a data-testid="news-document-card__title" href="https://pipelinereview.com/equillium-announces-positive-data-from-phase-2-study-evaluating-itolizumab-in-patients-with-moderate-to-severe-ulcerative-colitis/" rel="noopener" target="_blank">
            <!--[-->
            <span class="_title_1m6m5_1">
             Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
            </span>
            <!--]-->
           </a>
           <!--]-->
          </div>
          <!--[-->
          <div class="_container_16a6u_1 _containerStyle_16a6u_7 mt-2 hidden text-sm text-grey-450 md:block" style="--374e759f:60px;--661d8904:#1976d2;--470d35e6:20px;--78a7937a:20px;--cab18e14:#1976d2;--324c64a8:#1976d2;--8277a0b4:0px;">
           <div>
            <!--[-->
            <div data-testid="news-document-card__content" style="word-break:break-word;">
             Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Itolizumab was generally well tolerated consistent with prior clinical experience
LA JOLLA, CA, USA I February 06, 2025 I
Equillium, Inc.
(Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC).
The double-blinded, placebo- and active-controlled Phase 2 clinical study evaluated the safety and efficacy of itolizumab in biologic-naïve patients with moderate to severe active UC. A total of 90 patients were randomized 1:1:1 to receive itolizumab (fixed dose of 140 mg), placebo, or adalimumab (a global standard of care biologic treatment used as an active control) every two weeks for an initial 12-week treatment period. The primary endpoint of the study was clinical remission as defined by Total Mayo Score, and secondary endpoints included the proportion of participants who achieved clinical response and endoscopic remission (evaluated by central endoscopy). The study was co-sponsored by Equillium and Biocon Limited and conducted at multiple clinical trial sites in India. The design and conduct of the trial were a collaborative effort, with input from the gastroenterology community and leading global clinical and scientific experts in the field of inflammatory bowel disease (IBD).
“The CD6-ALCAM pathway is elevated in gastrointestinal inflammation and is associated with severity of disease in both ulcerative colitis and Crohn’s patients. As such, we are delighted with the strength of data across the primary and secondary endpoints of this Phase 2 study in moderate to severe ulcerative colitis patients,” said Dr. Stephen Connelly, chief scientific officer at Equillium. “Itolizumab was well tolerated and achieved a clinical remission rate of 23 percent despite an imbalance of more severe patients in the itolizumab arm compared to the other arms of the study. While these positive results add to itolizumab’s critical mass of safety and efficacy data across different patient populations, we are particularly encouraged by this data in the context of our Phase 3 EQUATOR study in acute graft-versus-host disease, where lower gastrointestinal pathogenesis is a key driver of mortality, with topline data expected this quarter.”
“Itolizumab demonstrated proof of concept with a meaningful effect size – comparable to biologic standard of care adalimumab – in this Phase 2 study in subjects with moderate to severe ulcerative colitis,” said Dr. Brian Feagan, Professor of Medicine at the Schulich School of Medicine &amp; Dentistry at the University of Western Ontario. “Itolizumab represents a novel selective immune modifying mechanism of action with great potential in a treatment paradigm needing differentiation and improved outcomes for patients.”
Summary of Key Study Results
Baseline demographics of the study included a median age of 39 years, relatively equal proportions of male and female subjects evenly distributed among study arms, and a mean weight of 58 kilograms.
Baseline disease severity of the study was greater in the itolizumab arm, where 23% of patients were classified as severe (Total Mayo Score of 11) versus 0% in the placebo and adalimumab arms, and 66% had left-sided colitis versus 30% and 43% in the placebo and adalimumab arms, respectively.
The primary endpoint of the study was clinical remission, defined as Total Mayo Score of ≤ 2 with no individual sub-score greater than 1 at Week 12. Secondary endpoints included the proportion of participants who achieved clinical response (per Total Mayo Score) and endoscopic remission (evaluated by central endoscopy) at Week 12 and Week 24. Additional data is expected to be presented at a future scientific conference during 2025.
* One patient from the adalimumab arm had ‘endoscopic remission,’ but was recorded as ‘not in clinical remission’ at week 12 due to missing sub-score data
About Itolizumab
Itolizumab is a clinical-stage, first-in-class immune-modifying monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases.
The blockade of CD6 with itolizumab has demonstrated a reduction in T effector cell proliferation and downregulation of several important pathways that contribute to T effector cell development. The downregulation of these pathways is accompanied by decreased secretion of the pro-inflammatory T effector cytokines IFN-γ, TNF-α, IL-6 and IL-17. Additionally, inhibiting the binding of ALCAM to CD6 modulates lymphocyte trafficking and results in reduced T effector cell infiltration into inflamed tissues.
About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe &amp; key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website:
www.biocon.com
; Follow-us on Twitter: @bioconlimited for company updates.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells that drive a number of immuno-inflammatory diseases. It is currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and has exhibited positive data from both a Phase 2 clinical study of patients with moderate to severe ulcerative colitis and a Phase 1b clinical study of patients with lupus/lupus nephritis. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited, who also provides commercial manufacturing for the product. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15, has exhibited positive results in both a Phase 2 proof-of-concept clinical study of patients with moderate to severe alopecia areata and a Phase 1/2 proof-of-concept clinical study of patients with cutaneous T cell lymphoma (CTCL). EQ302: an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21 at pre-clinical stage.
For more information, visit
www.equilliumbio.com
.
SOURCE:
Equillium
            </div>
            <!--]-->
           </div>
           <!-- -->
          </div>
          <!--]-->
         </div>
         <!-- -->
        </div>
        <div class="_content_afoc1_31">
         <!--[-->
         <div class="inline-flex max-w-full mt-2 flex flex-wrap justify-start">
          <!--[-->
          <div data-testid="news-document-card__tag">
           <!--[-->
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Clinical Result
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Phase 2
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Immunotherapy
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            License out/in
            <!--]-->
           </span>
           <!--]-->
          </div>
          <!--]-->
         </div>
         <!--]-->
        </div>
       </div>
      </div>
     </div>
     <!--]-->
    </div>
    <div class="_container_8x5ka_1 _newsCard_1m6m5_1 mt-3" data-testid="news-document-card">
     <!-- -->
     <!--[-->
     <div class="_container_afoc1_1 border">
      <div class="_subTitle_afoc1_14">
       <!--[-->
       <span class="">
        13 Nov 2024
       </span>
       <div class="hidden md:inline-block">
        <span class="px-1">
         ·
        </span>
        <a class="text-blue-500" href="https://www.equilliumbio.com/investors/press-releases/news-details/2024/Equillium-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-and-Clinical-Updates/default.aspx" rel="nofollow noopener" target="_blank">
         <!--[-->
         www.equilliumbio.com
         <!--]-->
        </a>
       </div>
       <!--]-->
      </div>
      <div class="mt-2 flex items-start">
       <div class="flex-1 overflow-hidden">
        <div class="flex">
         <div>
          <div class="_title_afoc1_6">
           <!--[-->
           <a data-testid="news-document-card__title" href="https://www.equilliumbio.com/investors/press-releases/news-details/2024/Equillium-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-and-Clinical-Updates/default.aspx" rel="noopener" target="_blank">
            <!--[-->
            <span class="_title_1m6m5_1">
             Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
            </span>
            <!--]-->
           </a>
           <!--]-->
          </div>
          <!--[-->
          <div class="_container_16a6u_1 _containerStyle_16a6u_7 mt-2 hidden text-sm text-grey-450 md:block" style="--374e759f:60px;--661d8904:#1976d2;--470d35e6:20px;--78a7937a:20px;--cab18e14:#1976d2;--324c64a8:#1976d2;--8277a0b4:0px;">
           <div>
            <!--[-->
            <div data-testid="news-document-card__content" style="word-break:break-word;">
             Equillium retains rights to itolizumab following substantial funding from Ono partnership
Evaluating accelerating Phase 3 EQUATOR study in aGVHD to completion in Q1 2025
Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided corporate and clinical updates.
“At the end of October we announced that our partnership with Ono Pharmaceutical had ended following substantial non-dilutive financing that has fully funded itolizumab research and development since July 2022. This funding enabled us to advance the program through two recent milestones – positive interim review from the Phase 3 EQUATOR study in acute graft-versus-host disease and positive topline data from the EQUALISE study in lupus nephritis. Ono informed us that their decision was strategic in nature, and that the data we have delivered from these studies met expectations with no observed or reported safety concerns,” said Bruce Steel, chief executive officer at Equillium. “We have enrolled over 150 patients in EQUATOR, and as of the end of October have temporarily paused enrollment to review clinical options for the program, including the potential to accelerate our timeline to topline data to the first quarter of 2025 while preserving registrational integrity of the study. We maintain orphan drug and fast track designations for first-line acute graft-versus-host disease, where currently no drugs are approved. In addition, in collaboration with Equillium, our partner Biocon has recently completed a robust placebo-controlled Phase 2 study of itolizumab in biologic-naïve patients with moderate to severe ulcerative colitis, and we expect topline data from this study also in the first quarter of 2025. We remain enthusiastic about the therapeutic potential and commercial opportunity for itolizumab, and we are very pleased to maintain our rights to the program as we approach the two most important data events in Equillium’s history.”
Highlights Since the Beginning of the Third Quarter of 2024:
Retained rights to itolizumab following Ono partnership Positive interim analysis of Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease subjects Phase 2 ulcerative colitis study completed by partner Biocon
Anticipated Upcoming Milestones:
Itolizumab: Topline data from Phase 2 study in ulcerative colitis – Q1 2025 Itolizumab: Topline data from Phase 3 EQUATOR study in aGVHD – potential acceleration to Q1 2025
Third Quarter 2024 Financial Results
Revenue for the third quarter of 2024 was $12.2 million, compared to $8.9 million during the same period in 2023. Revenue in the third quarters of 2024 and 2023 consisted entirely of itolizumab development funding and amortization of the upfront payment related to our former partnership with Ono.
Research and development (R&amp;D) expenses for the third quarter of 2024 were $9.6 million, compared to $9.0 million for the same period in 2023. The increase was primarily due to greater expenses associated with chemistry, manufacturing and controls (CMC) activities related to itolizumab, greater non-clinical research expenses, and an increase in employee compensation expenses, which were partially offset by lower clinical study expenses primarily driven by the EQUALISE and EQ101 clinical studies, partially offset by greater expenses for our EQUATOR clinical study.
General and administrative (G&amp;A) expenses for the third quarter of 2024 were $3.3 million, compared with $3.5 million for the same period in 2023. The decrease was primarily driven by lower legal, audit and tax professional fees.
Net loss for the third quarter of 2024 was approximately $7,000, or $(0.00) per basic and diluted share, compared with a net loss of $3.7 million, or $(0.11) per basic and diluted share, for the same period in 2023. The decrease in net loss was primarily attributable to greater revenue related to the Ono partnership, lower income tax expense, and other income, which were partially offset by the increase in R&amp;D expense.
Cash, cash equivalents and short-term investments totaled $25.9 million as of September 30, 2024, compared to $33.3 million as of June 30, 2024. Equillium believes that its cash, cash equivalents and short-term investments are sufficient to fund operations into the fourth quarter of 2025, assuming certain operational changes including accelerating the completion of the Phase 3 EQUATOR study based on reduced enrollment and early unblinding of the study, pausing further development activities related to EQ101 and EQ302, the elimination of certain positions and the reduction of certain discretionary expenditures, as well as assuming no further repurchases under our stock repurchase program.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells that drive a number of immuno-inflammatory diseases; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and announced positive data from a Phase 1b clinical study of patients with lupus/lupus nephritis in April 2024. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited, who also provides commercial manufacturing for the product. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; recently announced positive results from a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ302: an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21 at pre-clinical stage.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing itolizumab, including repositioning itolizumab as the top priority in the pipeline, anticipated upcoming milestones, timelines for topline data for itolizumab, the temporary pausing and potential acceleration of the EQUATOR study, the pausing of further activities related to EQ101 and EQ302, Equillium’s cash runway and related assumptions, and the potential benefits of Equillium’s product candidates. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical and pre-clinical studies; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; changes in Equillium’s strategic plans; uncertainties related to Equillium’s capital requirements and ability to obtain sufficient financing to fund Equillium’s strategic plans; the potential impact of the registrational integrity that would be caused by Equillium’s decision to accelerate the completion of EQUATOR; and having to use cash in ways or on timing other than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Equillium, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(unaudited)
September 30,
December 31,
2024
2023
Assets
Cash, cash equivalents and short-term investments
$
25,877
$
40,866
Accounts receivable
5,009
3,735
Prepaid expenses and other assets
3,098
5,133
Operating lease right-of-use assets
473
796
Total assets
$
34,457
$
50,530
Current liabilities
Accounts payable and other current liabilities
$
8,989
$
11,844
Current portion of deferred revenue
2,068
15,729
Total current liabilities
11,057
27,573
Long-term operating lease liabilities
223
384
Total liabilities
11,280
27,957
Total stockholders' equity
23,177
22,573
Total liabilities and stockholders' equity
$
34,457
$
50,530
Equillium, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(unaudited)
Three Months Ended September 30,
Nine Months Ended September 30,
2024
2023
2024
2023
Revenue
$
12,161
$
8,870
$
36,703
$
26,873
Operating expenses:
Research and development
9,562
8,974
30,113
27,855
General and administrative
3,278
3,519
10,161
10,340
Total operating expenses
12,840
12,493
40,274
38,195
Loss from operations
(679
)
(3,623
)
(3,571
)
(11,322
)
Total other income, net
672
409
1,298
893
Loss before income taxes
(7
)
(3,214
)
(2,273
)
(10,429
)
Income tax expense
-
496
-
564
Net loss
$
(7
)
$
(3,710
)
$
(2,273
)
$
(10,993
)
Net loss per share, basic and diluted
$
(0.00
)
$
(0.11
)
$
(0.06
)
$
(0.32
)
Weighted-average number of common shares outstanding, basic and diluted
35,424,388
34,878,700
35,324,092
34,582,574
Investor Contact Michael Moore Vice President, Investor Relations &amp; Corporate Communications 619-302-4431 ir@equilliumbio.com
            </div>
            <!--]-->
           </div>
           <!-- -->
          </div>
          <!--]-->
         </div>
         <!-- -->
        </div>
        <div class="_content_afoc1_31">
         <!--[-->
         <div class="inline-flex max-w-full mt-2 flex flex-wrap justify-start">
          <!--[-->
          <div data-testid="news-document-card__tag">
           <!--[-->
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Phase 2
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Clinical Result
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Fast Track
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Phase 3
            <!--]-->
           </span>
           <span class="_tag_5lm5p_1 _success_5lm5p_15 _small_5lm5p_31 mb-1 mr-2 cursor-pointer" data-testid="news-document-card__tag__item" style="background:;color:;">
            <!--[-->
            Financial Statement
            <!--]-->
           </span>
           <!--]-->
          </div>
          <!--]-->
         </div>
         <!--]-->
        </div>
       </div>
      </div>
     </div>
     <!--]-->
    </div>
    <!--]-->
   </div>
   <div class="mt-10 md:mt-12">
    <div class="mb-4 break-all text-sm text-black">
     <!--[-->
     <span class="_mosaic_dzucl_1">
      <!--[-->
      <span class="font-semibold text-seo-blue-500 underline">
       100
      </span>
      <!--]-->
     </span>
     <!--]-->
     <span>
      Deals associated with Itolizumab
     </span>
    </div>
    <div class="inline-flex max-w-full mt-4 w-full">
     <div class="_tipsContainer_b7pjb_1 _yellow_b7pjb_30 _tipsBorder_b7pjb_9" dialogtype="common" entrancetype="text" isallinforegister="false" showjumptip="true" size="medium" style="--28c9148e:4px;" type="default">
      <!--[-->
      <!--]-->
      <svg class="h-4 w-[10px]" fill="currentColor" height="1.2em" viewbox="0 0 10 16" width="1.2em">
       <path d="M9.70678 6.27142H5.92999L6.67408 0.15021C6.68107 0.0907286 6.65118 0.0334335 6.60111 0.0103023C6.55104 -0.0128288 6.49315 0.00392205 6.45976 0.0512057L0.0610803 9.20641C-0.00721034 9.30424 -0.0192403 9.43647 0.0300607 9.54737C0.0793617 9.65827 0.181418 9.72854 0.293217 9.72858H4.07001L3.32592 15.8498C3.31893 15.9093 3.34882 15.9666 3.39889 15.9897C3.44896 16.0128 3.50685 15.9961 3.54024 15.9488L9.93892 6.79359C10.0072 6.69576 10.0192 6.56353 9.96994 6.45263C9.92064 6.34174 9.81858 6.27146 9.70678 6.27142Z" fill-rule="evenodd">
       </path>
      </svg>
      <!--[-->
      <span class="_text_b7pjb_17">
       Login to view more data
      </span>
      <!--]-->
     </div>
    </div>
   </div>
   <!--]-->
  </div>
 </div>
 <div class="_item2_gldt3_15" id="external">
  <h3 class="_title_gldt3_1">
   <span>
    External Link
   </span>
  </h3>
  <div class="_content_gldt3_7">
   <!--[-->
   <div class="ant-table-wrapper" style="">
    <div class="ant-spin-nested-loading">
     <!-- -->
     <div class="ant-spin-container">
      <!--[-->
      <div class="ant-table ant-table-small ant-table-bordered" style="">
       <!-- -->
       <div class="ant-table-container">
        <div class="ant-table-content" style="">
         <table style="table-layout:auto;">
          <colgroup>
           <!--[-->
           <col style="width:25%;"/>
           <col style="width:25%;"/>
           <col style="width:25%;"/>
           <col style="width:25%;"/>
           <!--]-->
          </colgroup>
          <thead class="ant-table-thead">
           <!--[-->
           <tr>
            <!--[-->
            <th class="ant-table-cell" colend="0" colstart="0" style="">
             <!-- -->
             KEGG
             <!--[-->
             <!-- -->
             <!--]-->
            </th>
            <th class="ant-table-cell" colend="1" colstart="1" style="">
             <!-- -->
             Wiki
             <!--[-->
             <!-- -->
             <!--]-->
            </th>
            <th class="ant-table-cell" colend="2" colstart="2" style="">
             <!-- -->
             ATC
             <!--[-->
             <!-- -->
             <!--]-->
            </th>
            <th class="ant-table-cell" colend="3" colstart="3" style="">
             <!-- -->
             Drug Bank
             <!--[-->
             <!-- -->
             <!--]-->
            </th>
            <!--]-->
           </tr>
           <!--]-->
          </thead>
          <tbody class="ant-table-tbody">
           <!-- -->
           <!--[-->
           <!--[-->
           <tr class="ant-table-row ant-table-row-level-0" style="">
            <!--[-->
            <td class="ant-table-cell" style="">
             <!-- -->
             <span>
              <!--[-->
              -
              <!--]-->
             </span>
             <!-- -->
            </td>
            <td class="ant-table-cell" style="">
             <!-- -->
             <span>
              <!--[-->
              <a class="text-seo-blue-500" href="https://en.wikipedia.org/wiki/Itolizumab" rel="nofollow noopener" target="_blank">
               <!--[-->
               Itolizumab
               <!--]-->
              </a>
              <!--]-->
             </span>
             <!-- -->
            </td>
            <td class="ant-table-cell" style="">
             <!-- -->
             <span>
              <!--[-->
              <div class="flex flex-wrap">
               <!--[-->
               <a class="mr-1 text-seo-blue-500" href="https://www.whocc.no/atc_ddd_index/?code=L01XC&amp;showdescription=yes" rel="nofollow noopener" target="_blank">
                <!--[-->
                L01XC
                <!--]-->
               </a>
               <!--]-->
              </div>
              <!--]-->
             </span>
             <!-- -->
            </td>
            <td class="ant-table-cell" style="">
             <!-- -->
             <span>
              <!--[-->
              <div class="flex flex-wrap">
               <!--[-->
               <a class="mr-1 text-seo-blue-500" href="https://go.drugbank.com/drugs/DB16207" rel="nofollow noopener" target="_blank">
                <!--[-->
                DB16207
                <!--]-->
               </a>
               <!--]-->
              </div>
              <!--]-->
             </span>
             <!-- -->
            </td>
            <!--]-->
           </tr>
           <!-- -->
           <!--]-->
           <!--]-->
          </tbody>
          <!-- -->
         </table>
        </div>
       </div>
       <!-- -->
      </div>
      <!--]-->
     </div>
    </div>
   </div>
   <!--]-->
  </div>
 </div>
</div>
